21:17 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Vidac reports Phase IIa data for VDA-1102 in actinic keratosis

Vidac Pharma Ltd. (Jerusalem, Israel) said 10% VDA-1102 ointment missed the primary endpoint of reducing the mean number of actinic keratosis (AK) lesions on the face or scalp combined from baseline to day 56 vs....
20:34 , Jun 1, 2017 |  BC Innovations  |  Tools & Techniques

WuXi ex machina

Since its acquisition two years ago by New WuXi Life Science Ltd. , WuXi NextCode Genomics Inc. has been busy building out its artificial intelligence (AI) capabilities and test driving them via its expanding network...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Advising Israel

BC Staff  A new Israeli VC fund is leveraging a broad base of biopharma advisers to give its portfolio companies an advantage in development, partnering and commercialization activities. Israel Biotech Fund is raising its first...
01:06 , Jul 1, 2016 |  BC Extra  |  Financial News

Vidac raises $9M series A round

Vidac Pharma (Jerusalem, Israel) raised $9 million in a series A financing led by new investor Israel Biotech Fund. Existing investors including Mivtach Shamir Holdings also participated. The company's VDA-1102 ointment is in a Phase...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Company News

TransTech, Calithera Biosciences deal

TransTech granted cancer company Calithera exclusive, worldwide rights to develop and commercialize a portfolio of preclinical small molecule hexokinase 2 (HK2) inhibitors. TransTech will receive $600,000 up front and is eligible to receive up to...
07:00 , Oct 13, 2011 |  BC Innovations  |  Strategy

Lilly's opening moves

When Eli Lilly and Co. launched its Phenotypic Drug Discovery Initiative in 2009, its goal was to apply a crowdsourcing approach to finding new small molecules from external investigators that fit the company's core disease...
08:00 , Feb 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Glioblastoma multiforme (GBM) Hexokinase 2 (HK2) Studies in mice and in patient samples suggest that inhibiting HK2 could help treat GBM. In patient GBM...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Company News

Med Discovery, University of Lausanne deal

Med Discovery received exclusive, worldwide rights to the university's peptides derived from RAS p21 protein activator GTPase activating protein 1 ( RASA1 , RASGAP , p120GAP ), which have been shown to enhance the effect...